Lefamulin

Contraindicated

Lefamulin Dasatinib Phyrago Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Entrectinib Rozlytrek Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, increased entrectinib exposure, an increas... Details Lefamulin Ivabradine Corlanor Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Ketoconazole Topical Extina® Foam Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and an increased risk of QT interval prolon... Details Lefamulin Atazanavir Reyataz Increased lefamulin and atazanavir exposure and an increased risk of QT interval prolongation Details Lefamulin Bepridil An increased risk of QT interval prolongation Details Lefamulin Ceritinib Zykadia Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased sensitive CYP3A4 substrate ex... Details Lefamulin Cisapride Propulsid® Increased risk of QT interval prolongation Details Lefamulin Dronedarone Multaq Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased dronedarone exposure, an incr... Details Lefamulin Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Lefamulin Fluconazole Diflucan Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Lefamulin Ivosidenib Tibsovo Reduced lefamulin exposure, reduced efficacy of lefamulin, an increased ivosidenib exposure, an increased risk of ivosidenib-relat... Details Lefamulin Ketoconazole Extina Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and an increased risk of QT interval prolon... Details Lefamulin Levoketoconazole Recorlev An increased risk of QT interval prolongation and torsades pointes, an increased CYP3A4 substrate exposure and an increased risk o... Details Lefamulin Lomitapide Increased lomitapide exposure Details Lefamulin Mesoridazine An increased risk of QT interval prolongation Details Lefamulin Mobocertinib Exkivity Increased risk of QT interval prolongation Details Lefamulin Nilotinib Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased sensitive CYP3A4 substrate ex... Details Lefamulin Pimavanserin Nuplazid Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Pimozide Increased pimozide exposure, an increased risk of pimozide-related adverse reactions and an increased risk of QT interval prolonga... Details Lefamulin Piperaquine An increased risk of QT interval prolongation Details Lefamulin Posaconazole Noxafil Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Lefamulin Quetiapine Seroquel Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Quinidine Cardioquin® Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, increased sensitive CYP3A4 substrate expos... Details Lefamulin Quinine Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, increased sensitive CYP3A4 substrate expos... Details Lefamulin Repotrectinib Augtyro Reduced lefamulin exposure, reduced efficacy of lefamulin, an increased repotrectinib exposure and an increased risk of repotrecti... Details Lefamulin Ribociclib Kisqali Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased sensitive CYP3A4 substrate ex... Details Lefamulin Saquinavir Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased saquinavir exposure, an incre... Details Lefamulin Sparfloxacin An increased risk of QT interval prolongation Details Lefamulin Tacrolimus Astagraf Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Tamoxifen Nolvadex® Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Terfenadine An increased risk of QT interval prolongation Details Lefamulin Thioridazine Reduced lefamulin exposure, reduced efficacy of lefamulin and an increased risk of QT interval prolongation Details Lefamulin Vardenafil Levitra Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Lefamulin Voclosporin Lupkynis Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, increased voclosporin exposure, an increas... Details Lefamulin Ziprasidone Geodon An increased risk of QT interval prolongation Details

Major

Lefamulin Clindamycin ANTIROBE Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Lefamulin Amitriptyline Elavil Increased risk of QT interval prolongation Details Lefamulin Sertraline Increased risk of QT interval prolongation Details Lefamulin Buprenorphine Belbuca Increased risk of QT interval prolongation Details